Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
MBZUAI hosted a two-day workshop on "Big Model AI in Drug Design" starting February 20, 2023. The workshop featured presentations from researchers in public and private institutions working on AI and health. MBZUAI Adjunct Professor Eran Segal opened the workshop with a talk on the Human Phenotype Project. Why it matters: The event highlights the growing interest and activity in applying AI, particularly large models, to advance drug discovery and personalized medicine within the UAE's research ecosystem.
MBZUAI's Kun Zhang is applying causal machine learning to improve drug development and precision medicine, focusing on answering 'why' questions. Traditional drug development is costly (est. $2B) due to extensive studies needed to determine drug toxicity and efficacy. Zhang is combining causal ML with organs-on-chips technology to improve pre-clinical drug testing, aiming to reduce the failure rate of drugs in human trials. Why it matters: By improving the accuracy of pre-clinical drug testing, this research could significantly reduce the cost and time required to bring new medicines to market in the region and worldwide.
Adel Bibi, a KAUST alumnus and researcher at the University of Oxford, presented his research on AI safety, covering robustness, alignment, and fairness of LLMs. The research addresses challenges in AI systems, alignment issues, and fairness across languages in common tokenizers. Bibi's work includes instruction prefix tuning and its theoretical limitations towards alignment. Why it matters: This research from a leading researcher highlights the importance of addressing safety concerns in LLMs, particularly regarding alignment and fairness in the Arabic language.
Khaled Alsayegh at the King Abdullah International Medical Research Center is creating a Saudi Stem Cell Donor Registry, with 80,000 potential donors identified. The aim is to identify universal donors, reprogram their cells into induced pluripotent stem (iPS) cells, and create a gene bank for matched tissue transplants. Alsayegh is collaborating with Jesper Tegnér at KAUST to create pacemaker cells using single-cell RNA sequencing. Why it matters: This initiative could revolutionize precision medicine in KSA by providing readily available, matched cells for transplants, reducing the need for patient-specific reprogramming and improving treatment outcomes.
MBZUAI-based startup LibrAI has launched the Libra-Leaderboard, an evaluation framework for LLMs that assesses both capability and safety. The leaderboard evaluates 26 mainstream LLMs using 57 datasets, assigning scores based on bias, misinformation, and oversensitivity. LibrAI also launched the Interactive Safety Arena to engage the public and educate them on AI safety through adversarial prompt testing. Why it matters: The Libra-Leaderboard provides a benchmark for responsible AI development, emphasizing the importance of aligning AI capabilities with safety considerations in the rapidly evolving LLM landscape.